220 related articles for article (PubMed ID: 14632720)
1. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabet Med; 2003 Nov; 20(11):935-41. PubMed ID: 14632720
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy.
Furlong NJ; Hulme SA; O'Brien SV; Hardy KJ
Diabetes Care; 2002 Oct; 25(10):1685-90. PubMed ID: 12351462
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin.
Davies MJ; Thaware PK; Tringham JR; Howe J; Jarvis J; Johnston V; Kitchener DL; Skinner TC; McNally PG; Lawrence IG
Diabet Med; 2007 Jul; 24(7):714-9. PubMed ID: 17403126
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes.
Civera M; Merchante A; Salvador M; Sanz J; MartÃnez I
Diabetes Res Clin Pract; 2008 Jan; 79(1):42-7. PubMed ID: 17714824
[TBL] [Abstract][Full Text] [Related]
6. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of metformin and sitagliptin based triple antihyperglycemic therapy (STRATEGY): a multicenter, randomized, controlled, non-inferiority clinical trial.
Xu W; Mu Y; Zhao J; Zhu D; Ji Q; Zhou Z; Yao B; Mao A; Engel SS; Zhao B; Bi Y; Zeng L; Ran X; Lu J; Ji L; Yang W; Jia W; Weng J
Sci China Life Sci; 2017 Mar; 60(3):225-238. PubMed ID: 28271251
[TBL] [Abstract][Full Text] [Related]
8. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
Lund SS; Tarnow L; Frandsen M; Nielsen BB; Hansen BV; Pedersen O; Parving HH; Vaag AA
BMJ; 2009 Nov; 339():b4324. PubMed ID: 19900993
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Wang W; Bu R; Su Q; Liu J; Ning G
Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
[TBL] [Abstract][Full Text] [Related]
10. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
12. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
13. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
14. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
15. Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus.
Culy CR; Jarvis B
Drugs; 2001; 61(11):1625-60. PubMed ID: 11577798
[TBL] [Abstract][Full Text] [Related]
16. Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin.
Panelo A; Wing JR;
Diabetes Care; 2005 Jul; 28(7):1789-90. PubMed ID: 15983336
[No Abstract] [Full Text] [Related]
17. Combination-therapy with bedtime nph insulin and sulphonylureas gives similar glycaemic control but lower weight gain than insulin twice daily in patients with type 2 diabetes.
Olsson PO; Lindström T
Diabetes Metab; 2002 Sep; 28(4 Pt 1):272-7. PubMed ID: 12442064
[TBL] [Abstract][Full Text] [Related]
18. Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production.
Singhal P; Caumo A; Cobelli C; Taylor R
Metabolism; 2005 Jan; 54(1):79-84. PubMed ID: 15562384
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
20. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
[No Abstract] [Full Text] [Related]
[Next] [New Search]
